Pfizer (PFE) Ticks Higher on Expanded Lyrica Indication
Tweet Send to a FriendGet Alerts PFE Hot Sheet
Price: $28.96 -0.99%
Overall Analyst Rating:
BUY (
Up)
Dividend Yield: 3.5%
Revenue Growth %: -12.3%
Overall Analyst Rating:
BUY (
Up)Dividend Yield: 3.5%
Revenue Growth %: -12.3%
Trade PFE Now!
Pfizer (NYSE: PFE) shares are up early following news its Lyrica caps were approved by the FDA to manage neuropathic pain associated with spinal cord injury.
The stock is up 0.6 percent in early trade.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The stock is up 0.6 percent in early trade.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Mylan (MYL) Launches Generic Tricor Tabs (ABBV)
- UPDATE: Kansas City Southern (KSU) to Replace Dean Foods (DF) in S&P 500; WhiteWave Foods (WWAV) to S&P MidCap 400
Create E-mail Alert Related Categories
FDA, Insiders' Blog
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
